Why the study?
Chronic coronary syndrome is a leading cause of mortality with multiple therapeutic options, prompting an analysis of whether high ischemic risk cases should be managed invasively from the start.
Does initial invasive management improve mortality, cardiovascular events, or quality of life in patients with high ischemic risk chronic coronary syndrome?
Does initial invasive management improve mortality, cardiovascular events, or quality of life in patients with high ischemic risk chronic coronary syndrome?
Answers are grounded in this paper and cite their sources.
In patients with high-risk chronic coronary syndrome, an initial invasive strategy improves quality of life despite not significantly reducing mortality or hard cardiovascular events, which is particularly relevant in settings with limited access to acute care.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zegarra et al. (2020) conducted a review in Chronic coronary syndrome. Initial invasive management vs. Optimal medical therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: